State of Wyoming Invests $819,000 in Celcuity, Inc. $CELC

State of Wyoming acquired a new stake in Celcuity, Inc. (NASDAQ:CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 7,825 shares of the company’s stock, valued at approximately $819,000.

Several other institutional investors have also modified their holdings of the stock. EverSource Wealth Advisors LLC boosted its position in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the period. US Bancorp DE raised its position in Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Parallel Advisors LLC acquired a new stake in shares of Celcuity in the 1st quarter valued at $38,000. Finally, Meeder Asset Management Inc. acquired a new position in shares of Celcuity during the 4th quarter worth about $42,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

More Celcuity News

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Wall Street Analyst Weigh In

CELC has been the topic of several research reports. Wells Fargo & Company dropped their price objective on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Citigroup reissued an “outperform” rating on shares of Celcuity in a report on Wednesday, July 15th. HC Wainwright restated a “buy” rating and issued a $155.00 target price on shares of Celcuity in a research note on Friday. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Finally, Needham & Company LLC dropped their price target on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average price target of $153.64.

Celcuity Stock Up 6.2%

Shares of NASDAQ CELC opened at $92.00 on Friday. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 52 week low of $44.42 and a 52 week high of $151.02. The firm has a 50-day moving average price of $93.88 and a 200 day moving average price of $108.45. The stock has a market capitalization of $4.49 billion, a price-to-earnings ratio of -21.40 and a beta of 0.20.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities research analysts anticipate that Celcuity, Inc. will post -3.76 EPS for the current fiscal year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.